Skin Cancer Clinical Trials & Research at Providence Medical Group

Skin cancer is the most common type of cancer worldwide, with basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma being the primary subtypes. While BCC and SCC are generally less aggressive and highly treatable when detected early, melanoma is known for its potential to metastasize and become life-threatening. The increasing incidence of skin cancer underscores the urgent need for innovative treatments, making clinical trials essential for advancing patient care.

Clinical trials for skin cancer are at the forefront of developing and testing new therapies aimed at improving survival rates and quality of life. These trials evaluate a wide array of treatment modalities, including surgical techniques, radiation therapy, chemotherapy, targeted therapies, and immunotherapies. Recent advancements in immunotherapy, particularly immune checkpoint inhibitors, have revolutionized the treatment landscape for melanoma, offering new hope for patients with advanced disease.

Providence Medical Group is currently enrolling patients for the following skin cancer clinical trials:

No Clinical Trials